Acorda Therapeutics, Inc. (NASDAQ:ACOR)

CAPS Rating: 2 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Recs

0
Player Avatar jsgant13 (97.29) Submitted: 2/8/2011 9:38:25 PM : Outperform Start Price: $22.53 ACOR Score: +0.33

sac

Featured Broker Partners


Advertisement